Janux Therapeutics, Inc. Common Stock JANX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-14T01:47:26.919Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T21:00:01.654654045Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-14T01:47:25.747505+00:00
Janux Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.84 | 450.8% | 40.5% | |||
| 25Δ | 9.09 | 370.1% | 29.8% | |||
| 30Δ | 9.44 | 350.0% | 27.6% | |||
| 35Δ | 12.35 | 132.9% | 12.8% | 9.79 | 329.8% | 25.5% |
| 40Δ | 12.08 | 145.7% | 12.1% | 10.15 | 309.7% | 23.4% |
| 45Δ | 11.82 | 158.6% | 11.3% | 10.50 | 289.5% | 21.3% |
| 50Δ | 11.55 | 171.4% | 10.6% | 10.85 | 269.4% | 19.1% |
| 55Δ | 11.28 | 184.3% | 9.8% | 11.20 | 249.2% | 17.0% |
| 60Δ | 11.02 | 197.1% | 9.1% | 11.56 | 229.1% | 14.9% |
| 65Δ | 10.69 | 187.6% | 7.4% | 11.91 | 208.9% | 12.8% |
| 70Δ | 10.36 | 176.8% | 5.7% | 12.26 | 188.8% | 10.6% |
| 75Δ | 10.02 | 165.9% | 3.9% | 12.61 | 168.6% | 8.5% |
| 80Δ | 9.78 | 150.3% | 3.0% | 12.97 | 148.5% | 6.4% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.84
- IV
- 450.8%
- B/E move
- 40.5%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.09
- IV
- 370.1%
- B/E move
- 29.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.44
- IV
- 350.0%
- B/E move
- 27.6%
35Δ
- Pseudo strike
- 12.35
- IV
- 132.9%
- B/E move
- 12.8%
- Pseudo strike
- 9.79
- IV
- 329.8%
- B/E move
- 25.5%
40Δ
- Pseudo strike
- 12.08
- IV
- 145.7%
- B/E move
- 12.1%
- Pseudo strike
- 10.15
- IV
- 309.7%
- B/E move
- 23.4%
45Δ
- Pseudo strike
- 11.82
- IV
- 158.6%
- B/E move
- 11.3%
- Pseudo strike
- 10.50
- IV
- 289.5%
- B/E move
- 21.3%
50Δ
- Pseudo strike
- 11.55
- IV
- 171.4%
- B/E move
- 10.6%
- Pseudo strike
- 10.85
- IV
- 269.4%
- B/E move
- 19.1%
55Δ
- Pseudo strike
- 11.28
- IV
- 184.3%
- B/E move
- 9.8%
- Pseudo strike
- 11.20
- IV
- 249.2%
- B/E move
- 17.0%
60Δ
- Pseudo strike
- 11.02
- IV
- 197.1%
- B/E move
- 9.1%
- Pseudo strike
- 11.56
- IV
- 229.1%
- B/E move
- 14.9%
65Δ
- Pseudo strike
- 10.69
- IV
- 187.6%
- B/E move
- 7.4%
- Pseudo strike
- 11.91
- IV
- 208.9%
- B/E move
- 12.8%
70Δ
- Pseudo strike
- 10.36
- IV
- 176.8%
- B/E move
- 5.7%
- Pseudo strike
- 12.26
- IV
- 188.8%
- B/E move
- 10.6%
75Δ
- Pseudo strike
- 10.02
- IV
- 165.9%
- B/E move
- 3.9%
- Pseudo strike
- 12.61
- IV
- 168.6%
- B/E move
- 8.5%
80Δ
- Pseudo strike
- 9.78
- IV
- 150.3%
- B/E move
- 3.0%
- Pseudo strike
- 12.97
- IV
- 148.5%
- B/E move
- 6.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 75.12% | |
| 81.01% | |
| 75.82% | |
| 83.54% | |
| 83.26% | |
| 85.92% | |
| 77.26% | |
| 85.82% | |
| 82.77% | |
| 89.70% |
Biotechnology
JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and…
More →JBIO
Description unavailable
More →JSPR
Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for…
More →KARD
Kardigan, Inc. is an innovative technology company specializing in advanced software solutions for retail and e-commerce industries. With a strong focus on enhancing customer…
More →KLRA
Kailera Therapeutics, Inc. is a cutting-edge biotechnology company dedicated to developing innovative gene therapies for rare genetic diseases, addressing critical unmet medical…
More →KOD
Kodiak Sciences Inc., a clinical-stage biopharmaceutical company, is dedicated to researching, developing, and marketing therapies to treat retinal diseases in the United States…
More →